These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18971519)

  • 1. Renin-angiotensin system in the brain as a new target of antihypertensive therapy.
    Ito S; Komatsu K; Yajima Y; Hirayama A
    Hypertens Res; 2008 Aug; 31(8):1487-8. PubMed ID: 18971519
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prospects for pharmacological effects on renin-angiotensin and sympathetic nervous systems in patients with arterial hypertension].
    Chikhladze NM
    Ter Arkh; 2000; 72(12):67-9. PubMed ID: 11201840
    [No Abstract]   [Full Text] [Related]  

  • 3. [Renal sequelae of sympathetic hyperactivity].
    Watschinger B; Habicht A
    Wien Med Wochenschr; 2004; 154 Spec No 1(1):7-9. PubMed ID: 15346546
    [No Abstract]   [Full Text] [Related]  

  • 4. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Negrao CE; Negrao MV
    J Appl Physiol (1985); 2010 Dec; 109(6):2006. PubMed ID: 21188817
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there overlap in blood-pressure response to the blockers of the renin-angiotensin system between lower and higher renin subjects?
    Minami J; Ishimitsu T; Matsuoka H
    Am J Hypertens; 2008 Feb; 21(2):130-1; author reply 132. PubMed ID: 18268482
    [No Abstract]   [Full Text] [Related]  

  • 6. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
    Rohrwasser A
    J Appl Physiol (1985); 2010 Dec; 109(6):2007. PubMed ID: 21188818
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drugs and factors antagonizing the renin-angiotensin system].
    Brus R
    Postepy Hig Med Dosw; 1983; 37(3):271-85. PubMed ID: 6369280
    [No Abstract]   [Full Text] [Related]  

  • 8. [Blocking of the renin-angiotensin-aldosterone system in the study and treatment of arterial hypertension].
    Villarreal H
    Arch Inst Cardiol Mex; 1983; 53(1):1-3. PubMed ID: 6135394
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antihypertensive therapy. Pathophysiologic principles].
    Meurer KA; Kaufmann W
    MMW Munch Med Wochenschr; 1982 Nov; 124(47):1043-6. PubMed ID: 6817118
    [No Abstract]   [Full Text] [Related]  

  • 10. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hypertension combination therapy with renin-angiotensin system blockers].
    Soucek M
    Vnitr Lek; 2009 Sep; 55(9):719-23. PubMed ID: 19785368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension, the renin-angiotensin system and perindopril. First International Symposium on Perindopril. Paris, France, October 29, 1989.
    Clin Exp Hypertens A; 1989; 11 Suppl 2():459-623. PubMed ID: 2605797
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy of hypertensive hypertrophy.
    Motz W; Strauer BE
    Scand J Clin Lab Invest Suppl; 1989; 196():62-71. PubMed ID: 2530623
    [No Abstract]   [Full Text] [Related]  

  • 14. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
    Probstfield J
    J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
    [No Abstract]   [Full Text] [Related]  

  • 15. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Sympathetic nervous system, plasma volume, and hypertension.
    Christensen NJ
    J Appl Physiol (1985); 2010 Dec; 109(6):2003. PubMed ID: 21188813
    [No Abstract]   [Full Text] [Related]  

  • 16. Ramipril: the better angiotensin-converting enzyme inhibitor?
    Gupta R
    Indian Heart J; 2008; 60(3):188-91. PubMed ID: 19240304
    [No Abstract]   [Full Text] [Related]  

  • 17. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activated intrarenal renin-angiotensin system is correlated with high blood pressure in humans.
    Kobori H; Fu Q; Crowley SD; Gonzalez-Villalobos RA; Campos RR
    J Appl Physiol (1985); 2010 Dec; 109(6):2003. PubMed ID: 21148352
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term drug therapy of arterial hypertension including patient compliance].
    Linss G; Kiesewetter R
    Z Arztl Fortbild (Jena); 1984; 78(24):1047-53. PubMed ID: 6442069
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventing microalbuminuria in type 2 diabetes.
    Mauer M; Fioretto P
    N Engl J Med; 2005 Feb; 352(8):833-4; author reply 833-4. PubMed ID: 15736290
    [No Abstract]   [Full Text] [Related]  

  • 20. [Kidney and hypertension].
    Menne J; Fliser D; Haller H
    Herz; 2006 Jun; 31(4):317-21. PubMed ID: 16810471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.